INSIGHTS ON CELL & GENE CLINICAL TRIALS

• Galvanizing Large And Small For Clinical Success

  See how two academic investigators accelerated corneal regeneration and lung fibrosis therapies from preclinical research to clinical trials by leveraging scalable GMP solutions and regulatory-ready materials.

• 10 Clinical Research Practices That Feel Like Compliance (But Aren't)

  Many clinical research routines are driven by habit, not regulation. This guide clears up 10 common misconceptions to streamline workflows and reduce unnecessary admin work.

• Zymeworks Shares Its Design Rationale (And Wins) In Early-Phase ADC Trials

  Zymeworks CMO Sabeen Mekan, MD, explores how scientific gains in ADC therapies have influenced first-in‑human trial design.

• Overcome Patient-Level Access Barriers For New Medicine

  Explore market access from the patient’s perspective and identify five aspects of how people get hold of medicine that should inform commercialization.

• Compliance, Costs, And Site Readiness In CAR-T Clinical Trials

  Navigate CAR-T trial complexity: uncover key compliance, budgeting, and site readiness strategies to ensure safe, efficient, and successful patient care.

• Managing Operational Challenges In CAR-T Clinical Trial Logistics

  Coordinating CAR-T trials means managing tight timelines, cryogenic handling, staffing gaps, and chain-of-identity risks where even small missteps can delay care.

• Lessons From Bringing A Novel T Cell Class For Autoimmune Diseases Into The Clinic

  Tr1X Bio Co-founder and CEO David de Vries explains how moving Type 1 regulatory T Cell (Tr1) therapies into new indications reshapes every facet of first-in-human trial design.

• Why AI Matters In Early Phase Clinical Trials

  AI speeds early‑phase development by streamlining data review, enabling structured queries, accelerating PK/PD work, and revealing biomarker patterns — boosting efficiency with expert oversight.

• Unanticipated Roadblocks In Ovarian Cancer Drug Development

  Ovarian cancer trials require specialized strategies that go beyond generic tumor designs. Enhance your program by enabling community referral pipelines, aligning imaging with biomarker assessments, and selecting sites based on verifiable surgical capacity.

• The Bioanalysis CRO Selection Checklist Every Sponsor Should Use Before Signing An MSA

  Choosing a CRO requires more than proposals. Assess reliability, automation, GLP rigor, scientific engagement, pricing clarity, and capacity to find partners who deliver defensible data on real timelines.